Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Stock Info
Posted On: 07/07/2014 11:53:28 AM
Post# of 250668
Posted By: Jerseyfish
GNSZ
GenSpera harnesses a novel biomedical technology platform to deliver a powerful toxin directly to tumors

Phase II clinical trials for lead compound, G-202, are underway in two indications:
Hepatocellular carcinoma, or liver cancer
Glioblastoma, or brain cancer
Experienced and motivated team drives the process:
Core team has extensive experience in successfully identifying and bringing oncology treatments to the clinic.
Scientific Advisory Board is comprised of leading researchers who are both the inventors of the technology and shareholders.
Technology platform supports the development of a suite of drugs targeted at different cancers, as well as other applications such as imaging.
Over 15 years of research at Johns Hopkins Medical Center and other renowned research centers, including the University of Copenhagen.
Strong intellectual property portfolio
No milestones or royalty payments owed to third parties.
Leverage the team's passion and expertise in identifying promising treatments and bringing them to the clinic.


Slide1.png

(0)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site